Effect of Intravitreal Bevacizumab on Focal Edema With Hard Exudates Secondary to Diabetic Retinopathy
|ClinicalTrials.gov Identifier: NCT01422018|
Recruitment Status : Unknown
Verified September 2011 by Won Ki Lee, Seoul St. Mary's Hospital.
Recruitment status was: Recruiting
First Posted : August 23, 2011
Last Update Posted : September 23, 2011
Purpose: To evaluate the efficacy of intravitreal bevacizumab (IVB) on focal edema with hard exudates secondary to diabetic retinopathy.
Design: Prospective interventional case series. Participants: Ten eyes of 10 consecutive patients showing focal edema with hard exudates secondary to diabetic retinopathy which are not eligible for focal laser photocoagulation due to central location (< 500 µm from fovea).
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Complications||Drug: Avastin (bevacizumab)||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||August 2011|
|Estimated Primary Completion Date :||February 2012|
|Estimated Study Completion Date :||February 2012|
Experimental: one arm for Anastin injection
intravitreal Avastin injection
Drug: Avastin (bevacizumab)
Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA)
- Changes in best-corrected visual acuity (BCVA) [ Time Frame: from month 0 to month 6 in monthly schedule (upto 6 months) ]ETDRS BCVA will be measured after 6 6 serial IVB.
- amount of hard exudates detected on fundus photography [ Time Frame: from month 0 to month 6 in bimonthly schedule (upto 6 months) ]on fundus photography
- macular edema detected by optical coherent tomography [ Time Frame: from month 0 to month 6 in bimonthly schedule (upto 6 months) ]central subfield thickness will be measured.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01422018
|Contact: Sohee Jeon, MDfirstname.lastname@example.org|
|Contact: Won ki Lee, DM, Ph.Demail@example.com|
|Korea, Republic of|
|Seoul St Mary's hospital||Recruiting|
|Seocho, Seoul, Korea, Republic of, 137-070|
|Contact: Sohee Jeon, MD 82-10-7176-1357 firstname.lastname@example.org|
|Principal Investigator:||Won ki Lee, MD Ph.D||Seoul St. Mary's Hospital|